CJC-1295/Ipamorelin

Overview

A grey-market pre-mixed blend of CJC-1295 (no DAC / Modified GRF 1-29), a GHRH analog, and Ipamorelin, a selective ghrelin-receptor agonist. The blend itself is NOT clinically validated — no controlled human trial has tested this specific combination. The pharmacological rationale (GHRH + GHRP synergy for pulsatile GH amplification) is inferred from studies of other GHRH/GHRP pairs.

Mechanism of Action

CJC-1295 (no DAC / Modified GRF 1-29) binds the pituitary GHRH receptor to stimulate GH release, while Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist that does not meaningfully elevate cortisol or prolactin. Any additive or synergistic GH response in humans is extrapolated from studies of other GHRH + GHRP combinations; it has not been directly demonstrated for this specific blend.

Research Summary

Each component is characterized in isolation, but no published human trial has tested the CJC-1295 (no DAC) + Ipamorelin combination. The "no DAC" specification distinguishes Modified GRF 1-29 (half-life ~30 min, pulsatile) from CJC-1295 with DAC (albumin-bound, multi-day half-life) — these are pharmacokinetically distinct molecules and should not be conflated. The often-cited Teichman 2006 JCEM trial studied CJC-1295 WITH DAC, not the no-DAC form and not a combination with Ipamorelin.

Dosing Information

Reported Side Effects

• See individual compound profiles for CJC-1295 and Ipamorelin

Labs to monitor before & during your CJC-1295/Ipamorelin protocol

These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.

Commonly Stacked With

Research References

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
• Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-E1092. PMID 19240251. https://pubmed.ncbi.nlm.nih.gov/19240251/